Intercept Pharmaceutical Stock Sees RS Rating Rise To 91
When looking for the best stocks to buy and watch, focus on those with rising relative price strength.
One stock that fits that bill is Intercept Pharmaceutical (ICPT) stock, which saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, rising from 80 to 91.
X
When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. This unique rating identifies market leadership by showing how a stock’s price action over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research reveals that the top-performing stocks tend to have an RS Rating of above 80 as they launch their biggest runs.
Looking For The Best Stocks To Buy And Watch? Start Here
Intercept Pharmaceutical Stock A Buy?
While it’s not currently an ideal time to buy shares of Intercept Pharmaceutical stock, see if the stock is able to establish and enter a buy zone in heavy trade. Look for the stock market outlook to rally in a confirmed uptrend before adding stocks.
Earnings grew 10% last quarter, up from 0% in the prior report. Revenue also increased, from 3% to 5%.
Intercept Pharmaecutical stock holds the No. 100 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharma (CPRX), Vertex Pharmaceuticals (VRTX) and Amphastar Pharmaceutcls (AMPH) are among the top 5 highly rated stocks within the group. For more industry news, check out “Biotech And Pharmaceutical Industry And Stock News.”
IBD Newsletters
Get exclusive IBD analysis and actionable news daily.
SIGN UP NOW!
IBD Newsletters
Get exclusive IBD analysis and actionable news daily.
Please enter a valid email address
Please select a newsletter
GO
Get these newsletters delivered to your inbox & more info about our products & services. Privacy Policy & Terms of Use
x
Thank You!
You will now receive IBD Newsletters
ALL DONE!
Something Went Wrong!
Please contact customer service
CLOSE
YOU MIGHT ALSO LIKE:
MarketSmith’s Tools Can Help The Individual Investor
IBD Live: A New Tool For Daily Stock Market Analysis
Profit From Short-Term Trends With SwingTrader
How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
No Byline Policy
Editorial Guidelines
Corrections Policy
Source